Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs Navio MD

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Navio MD a 75. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$99/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

Navio MD

#138 · Grade C+ · Fair Price

Est. first month

From $189/mo (compounded)

Save ~86% vs brand-name
Get this deal Full Navio MD review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 75 an est. $99/mo first month, with no teaser step-up baked in. Navio MD isn't out of it: Someone who wants tirzepatide specifically, or a brand-name Ozempic route on the same account.

CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxNavio MD
Value Score93 (A+)75 (C+)
Est. first month$99/moFrom $189/mo (compounded)
Save vs brand-name~89%~86%
Semaglutide$99/moNot disclosed (compounded); brand Ozempic from $345/mo
Tirzepatide$149/moFrom $189/mo (compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 states48 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
74
CoreAge Rx: 88. Navio MD: 74.
98
No Teaser-Rate Bait
64
CoreAge Rx: 98. Navio MD: 64.
98
Nationwide Availability
88
CoreAge Rx: 98. Navio MD: 88.
95
Both Molecules
92
CoreAge Rx: 95. Navio MD: 92.
95
Easy Cancellation
58
CoreAge Rx: 95. Navio MD: 58.
84
Reputation
82
CoreAge Rx: 84. Navio MD: 82.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

Navio MD

NavioMD sells compounded tirzepatide from $189 a month across 48 states, with brand-name Ozempic from $345 for anyone who wants semaglutide instead.

Why it's a deal

  • Compounded tirzepatide from $189 is below the roughly $249 tirzepatide median tracked here
  • Brand-name Ozempic is offered and priced openly at $345 rather than quoted after an intake
  • Operates across 48 states and names the two it does not serve
  • Treatment, provider access and delivery are handled in one flow with no separate membership

The fine print

  • No compounded semaglutide at all — if you want semaglutide here it is brand-name at $345
  • Not available in Alabama or Mississippi
  • The advertised figures are "as low as" rates and the site does not publish what higher doses cost
  • Women's hormone therapy sits alongside the weight program, so GLP-1s are one line rather than the focus
Get the CoreAge Rx deal Get the Navio MD deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Navio MD.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.